5-((benzyloxy)methyl)-5-methylimidazolidine-2,4-dione | 191110-57-3

• 分子结构分类: 有机化合物
• 英文名称: 5-((benzyloxy)methyl)-5-methylimidazolidine-2,4-dione
• 英文别名: 5-Methyl-5-(phenylmethoxymethyl)imidazolidine-2,4-dione
• CAS: 191110-57-3
• 化学式: C₁₂H₁₄N₂O₃
• 分子量: 234.255
• InChiKey: FPSQXDLFGOQULK-UHFFFAOYSA-N

物化性质

• 熔点：
  94.5-96 °C(Solv: ethyl acetate (141-78-6))
• 密度：
  1.190±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  67.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-((benzyloxy)methyl)-5-methylimidazolidine-2,4-dione 在 sodium hydroxide 、 sodium hydride 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-benzyloxy-2-[N-(tert-butoxycarbonyl)methylamino]-2-methylpropanoic acid tert-butyl ester
  参考文献：
  名称：

  McConathy, J.; Martarello, L.; Goodman, M. M., Journal of labelled compounds and radiopharmaceuticals, 2001, vol. 44, p. S376 - S378

  摘要：

  DOI：
• 作为产物：
  描述：

  苄氧基丙酮 、 氰化钾 在 碳酸氢铵 、 氯化铵 作用下， 以 乙醇 、 水 为溶剂， 生成 5-((benzyloxy)methyl)-5-methylimidazolidine-2,4-dione
  参考文献：
  名称：

  McConathy, J.; Martarello, L.; Goodman, M. M., Journal of labelled compounds and radiopharmaceuticals, 2001, vol. 44, p. S376 - S378

  摘要：

  DOI：

文献信息

• Tumor imaging compounds
  申请人：Goodman M. Mark

  公开号：US20050192458A1

  公开（公告）日：2005-09-01

  The invention provides novel amino acid compounds of use in detecting and evaluating brain and body tumors. These compounds combine the advantageous properties of α-aminoisobutyric acid (AIB) analogs namely, their rapid uptake and prolonged retention in tumors with the properties of halogen sustituents, including certain useful halogen isotopes such as fluorine-18, iodine-123, iodine-124, iodine-125, iodine-131, bromine-75, bromine-76, bromine-77, bromine-82, astatine-210, astatine-211, and other astatine isotopes. In addition the compounds can be labeled with technetium and rhenium isotopes using known chelation complexes. The amino acid compounds disclosed herein have a high specificity for target sites when administered to a subject in vivo. Preferred amino acid compounds include [ 18 F] FAMP, ([ 18 F]5a) and [ 18 F]N-MeFAMP, ([ 18 F]5b). The invention further features pharmaceutical compositions comprised of an α-amino acid moiety attached to eiher a four, five or a six member carbon-chain ring. The labeled amino acid compounds are useful as imaging agents in detecting and/or monitoring tumors in a subject by Positron Emission Tomography (PET) and Single Photon Emission Computer Tomography (SPECT).

  该发明提供了一种新型氨基酸化合物，用于检测和评估大脑和身体肿瘤。这些化合物结合了α-氨基异丁酸（AIB）类似物的有利特性，即它们在肿瘤中的快速摄取和长时间滞留，以及卤素取代物的特性，包括某些有用的卤素同位素，如氟-18、碘-123、碘-124、碘-125、碘-131、溴-75、溴-76、溴-77、溴-82、砹-210、砹-211和其他砹同位素。此外，这些化合物可以使用已知的螯合配合物标记为锝和铼同位素。本文披露的氨基酸化合物在体内给予受试者时对靶位点具有高特异性。优选的氨基酸化合物包括[18F] FAMP，([18F]5a)和[18F]N-MeFAMP，([18F]5b)。该发明进一步涉及由α-氨基酸基团连接到四、五或六元碳链环的药物组合物。标记的氨基酸化合物可用作影像剂，通过正电子发射断层扫描（PET）和单光子发射计算机断层扫描（SPECT）检测和/或监测受试者体内的肿瘤。
• [EN] 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS<br/>[FR] DÉRIVÉS DE 1,2,4-OXADIAZOLE EN TANT QU'AGONISTES DU RÉCEPTEUR X DU FOIE
  申请人：NOVARTIS AG

  公开号：WO2021105857A1

  公开（公告）日：2021-06-03

  Provided herein are compounds and pharmaceutical compositions useful for treating meibomian gland dysfunction (MGD), comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a compound of Formula (I'), or pharmaceutical composition described herein.

  本文提供了用于治疗睑腺功能障碍（MGD）的化合物和药物组合物，包括向需要的受试者施用公式（I）的化合物或公式（I'）的化合物的治疗有效量，或本文所描述的药物组合物。
• TUMOR IMAGING COMPOUNDS
  申请人：Goodman Mark M.

  公开号：US20090240041A1

  公开（公告）日：2009-09-24

  The invention provides novel amino acid compounds of use in detecting and evaluating brain and body tumors. These compounds combine the advantageous properties of α-aminoisobutyric acid (AIB) analogs namely, their rapid uptake and prolonged retention in tumors with the properties of halogen substituents, including certain useful halogen isotopes such as fluorine-18, iodine-123, iodine-124, iodine-125, iodine-131, bromine-75, bromine-76, bromine-77, bromine-82, astatine-210, astatine-211, and other astatine isotopes. In addition the compounds can be labeled with technetium and rhenium isotopes using known chelation complexes. The amino acid compounds disclosed herein have a high specificity for target sites when administered to a subject in vivo. The labeled amino acid compounds are useful as imaging agents in detecting and/or monitoring tumors in a subject by Positron Emission Tomography (PET) and Single Photon Emission Computer Tomography (SPECT).

  本发明提供了新型氨基酸化合物，用于检测和评估大脑和身体肿瘤。这些化合物结合了α-氨基异丁酸（AIB）类似物的优越性能，即它们在肿瘤中的快速摄取和长时间保留，以及卤素取代基的性质，包括某些有用的卤素同位素，如氟-18，碘-123，碘-124，碘-125，碘-131，溴-75，溴-76，溴-77，溴-82，砹-210，砹-211和其他砹同位素。此外，这些化合物可以使用已知的螯合配合物标记为锝和铼同位素。在体内给予受试者时，本文所披露的氨基酸化合物具有高度特异性的靶向位点。标记的氨基酸化合物可用作成像剂，通过正电子发射断层扫描（PET）和单光子发射计算机断层扫描（SPECT）检测和/或监测受试者的肿瘤。
• [EN] USE OF 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS<br/>[FR] UTILISATION DE DÉRIVÉS DE 1,2,4-OXADIAZOLE EN TANT QU'AGONISTES DU RÉCEPTEUR X DU FOIE
  申请人：NOVARTIS AG

  公开号：WO2022249006A1

  公开（公告）日：2022-12-01

  Provided herein are compounds and pharmaceutical compositions useful for treating atopic dermatitis, contact dermatitis, chronic hand dermatitis, psoriasis, vitiligo, and alepecia areata, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a compound of Formula (I'), or pharmaceutical composition described herein. (I) (I')

  本文提供的化合物和药物组合物可用于治疗特应性皮炎、接触性皮炎、慢性手部皮炎、银屑病、白癜风和斑秃，包括向需要治疗的受试者施用公式(I)或公式(I')的化合物或药物组合物的治疗有效量。 (I) (I')
• Radiolabeled Amino Acids for Tumor Imaging with PET:  Radiosynthesis and Biological Evaluation of 2-Amino-3-[¹⁸F]fluoro-2-methylpropanoic Acid and 3-[¹⁸F]Fluoro-2-methyl-2-(methylamino)propanoic Acid
  作者：Jonathan McConathy、Laurent Martarello、Eugene J. Malveaux、Vernon M. Camp、Nicholas E. Simpson、Chiab P. Simpson、Geoffrey D. Bowers、Jeffrey J. Olson、Mark M. Goodman

  DOI：10.1021/jm010241x

  日期：2002.5.1

  Novel radiopharmaceuticals, including amino acids, that target neoplasms through their altered metabolic states have shown promising results in preclinical and clinical studies. Two fluorinated analogues of alpha-aminoisobutyric acid, 2-amino-3-fluoro-2-methylpropanoic acid (FAMP) and 3-fluoro-2-methyl-2-(methylamino)propanoic acid (N-MeFAMP), have been radiolabeled with fluorine-18, characterized in amino acid uptake assays, and evaluated in vivo in normal rats and a rodent tumor model. The key steps in the syntheses of both radiotracers involved the preparation of cyclic sulfamidate precursors. Radiosyntheses of both [F-18]FAMP and [F-18]N-MeFAMP via no-carrier-added nucleophilic substitution provided high yields (>78% decay-corrected) in high radiochemical purity (>99%). Amino acid transport assays using 9L gliosarcoma cells demonstrated that both compounds are substrates for the A type amino acid transport system, with [F-18]N-MeFAMP showing higher specificity than [F-18] FAMP for A type transport. Tissue distribution studies in normal Fischer rats and Fischer rats implanted intracranially with 9L gliosarcoma tumor cells were also performed. At 60 min postinjection, the tumor vs normal brain ratio of radioactivity was 36:1 in animals receiving [F-18] FAMP and 104:1 in animals receiving [F-18]N-MeFAMP. On the basis of these studies, both [F-18]FAMP and [F-18]N-MeFAMP are promising imaging agents for the detection of intracranial neoplasms via positron emission tomography.